Therefore, a combination therapy involving XPO1 and KRAS G12C inhibitors can be a viable option, especially considering that preclinical and clinical studies have already reported the emergence of resistant subpopulations of cancer cells in response to KRAS G12C inhibitor monotherapy (13–16). Here, KRAS is linked to cancer.